Cunningham v. Charles Pfizer & Co., Inc.

532 P.2d 1377
CourtSupreme Court of Oklahoma
DecidedMarch 26, 1975
Docket46237
StatusPublished
Cited by54 cases

This text of 532 P.2d 1377 (Cunningham v. Charles Pfizer & Co., Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Oklahoma primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cunningham v. Charles Pfizer & Co., Inc., 532 P.2d 1377 (Okla. 1975).

Opinion

BERRY, Justice :

Plaintiff brought this action to recover damages for injuries allegedly sustained from ingesting oral polio vaccine manufactured by Charles Pfizer & Company, Inc. [defendant].

The jury returned a verdict for plaintiff for $340,000 and the trial court entered judgment accordingly. Defendant appeals. For reasons hereinafter stated we conclude the judgment of the trial court must be reversed and remanded for a new trial.

The Sabin oral vaccine contains live attenuated polio virus. Producers of the vaccine, including defendant, are licensed by the United States Government.

There are three types of polio virus, Type I, Type II and Type III. There are three corresponding types of monovalent Sabin vaccine, Type I, Type II and Type *1379 III. One must take each vaccine in order to be immunized against all three polio viruses.

There is also a trivalent vaccine which contains all three types of attenuated viruses.

Prior to 1963 the Surgeon General appointed a committee to investigate cases of polio which might have been caused by the vaccine.

In 1963 the Tulsa County Medical Society and the Tulsa City-County Health Department sponsored a mass polio immunization clinic using Sabin oral polio vaccine manufactured by defendant.

A licensed doctor was available at each distribution point to answer questions.

It was stipulated that the vaccine furnished by defendant was produced and manufactured in accordance with U. S. Government specifications.

The evidence indicated members of the medical society sponsoring the program were aware of all existing information concerning any relationship between ingestion of the vaccine and the onset of polio. However, defendant made no effort to furnish this information to participants in the mass- immunization program.

On January 20, 1963, plaintiff, who was IS years old at the time, took Type I vaccine as a part of this program. Defendant gave no direct warning to plaintiff or his parents concerning possible untoward effects of the vaccine.

Within five weeks after he took the vaccine plaintiff contracted a paralytic disease.

Plaintiff’s theory in the trial court was to the effect defendant failed to warn him, or his parents, of the risk of contracting polio from the polio vaccine, and this failure to warn rendered defendant liable for all damages plaintiff incurred as a result of taking the vaccine.

Defendant’s theory in the trial court was to the effect plaintiff did not contract polio, that if he did, he did not contract it from defendant’s vaccine, and defendant had no duty to warn ultimate consumers of risks involved in taking the vaccine, but only had a duty to warn members of the medical society sponsoring the program.

The trial court adopted plaintiff’s theory. The court’s instruction 7 set out this theory as follows:

“You are instructed that a manufacturer of polio vaccine has the duty to warn consumers of the risks involved in taking-the vaccine or the vaccine is considered as being in an unfit condition, thereby being unreasonably dangerous, and subjecting the manufacturer to liability for physical harm caused to the consumer of the vaccine.”

Defendant excepted to this instruction.

The remainder of the instructions indicate the only issues submitted to the jury were (1) whether plaintiff contracted polio (2) whether he contracted it from taking defendant’s vaccine and (3) the amount of damages.

On appeal defendant first contends the trial court erred in applying the theory of strict liability in tort to this case. In Kirkland v. General Motors Corp., Okl., 521 P.2d 1353, we adopted the theory of strict liability in tort set out in Restatement of Torts, 2nd Ed. § 402A. This principle is to the effect that one who sells a product in a defective condition unreasonably dangerous to the user or consumer or to his property is liable for physical harm thereby caused to the ultimate user or consumer or to his property (a) if the seller is engaged in the business of selling such a product and (b) it is expected to and does reach the user and consumer without substantial change in the condition in which it is sold.

In that case we stated:

“* * * we specifically hold that the law hereby established will be applied prospectively to all cases for trial from and after the date the mandate issues herein; and may likewise be applied by the appellate courts in cases which have been tried and are for decision on appeal where it would not prejudice the rights of the litigants.”

*1380 Defendant contends the trial court erred in applying the theory in this case because this case was tried prior to the time the manda'te issued in Kirkland v. General Motors Corp., supra.

If we were to reverse the trial court’s judgment on this ground, the trial court could apply the principles of Kirkland in the new trial. Furthermore, we note defendant’s theory at trial was that the case was governed by strict liability in tort but that theory did not impose liability upon defendant under the facts in this case. Therefore, we conclude the principles enunciated in Kirkland are applicable to this appeal.

Defendant next contends the evidence was insufficient to establish plaintiff contracted polio as a result of taking defendant’s vaccine.

We note there was medical testimony which tended to establish plaintiff’s injuries were sustained as a result of taking defendant’s vaccine.

Defendant next contends the trial court erred in submitting the case to the jury because there was no proof of a defect in the vaccine.

Subsection k of the comments under § 402A, supra, states:

“k. Unavoidably unsafe products.
“There are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use. These are especially common in the field of drugs. * * * Such a product, properly prepared, and accompanied by proper directions and warning, is not defective nor is it unreasonably dangerous. The same is true of many other drugs, vaccines, and the like, many of which for this very reason cannot legally be sold except to physicians, or under the prescription of a physician. * * * The seller of such products, again with the qualification that they are properly prepared and marketed, and proper warning is given, where the situation calls for it, is not to be held to strict liability for unfortunate consequences attending their use merely because he has undertaken to supply the public with an apparently useful and desirable product, attended with a known hut apparently reasonable risk.”

In applying § 402A, supra, courts have construed this comment to mean that in certain circumstances a drug manufacturer has a duty to ensure consumers are warned of known risks involved in taking a drug and a failure to fulfill this duty renders the drug defective within the meaning of § 402A, supra. Davis v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

COMBS v. BAYER AG
Court of Civil Appeals of Oklahoma, 2026
STATE ex rel. ATTORNEY GENERAL OF OKLAHOMA v. JOHNSON & JOHNSON
2021 OK 54 (Supreme Court of Oklahoma, 2021)
Shepherd v. Eli Lilly and Company
497 F. App'x 143 (Second Circuit, 2012)
Moore v. Ford Motor Co.
332 S.W.3d 749 (Supreme Court of Missouri, 2011)
Rivera v. Philip Morris, Inc.
209 P.3d 271 (Nevada Supreme Court, 2009)
Riegel v. Medtronic, Inc.
552 U.S. 312 (Supreme Court, 2008)
Larkin v. Pfizer, Inc.
153 S.W.3d 758 (Kentucky Supreme Court, 2004)
Eck v. Parke, Davis & Co.
256 F.3d 1013 (Tenth Circuit, 2001)
Akin v. Big Three Industries
156 F.3d 1030 (Tenth Circuit, 1998)
Akin v. Ashland Chemical Co.
156 F.3d 1030 (Third Circuit, 1998)
Woulfe v. Eli Lilly & Co.
965 F. Supp. 1478 (E.D. Oklahoma, 1997)
Edwards v. Basel Pharmaceuticals
1997 OK 22 (Supreme Court of Oklahoma, 1997)
Daniel v. Ben E. Keith Company
97 F.3d 1329 (Tenth Circuit, 1996)
House v. Armour of America, Inc.
886 P.2d 542 (Court of Appeals of Utah, 1994)
Juvenal Ex Rel. Juvenal v. Okeene Public Schools
1994 OK 83 (Supreme Court of Oklahoma, 1994)
Coffman v. Keene Corp.
628 A.2d 710 (Supreme Court of New Jersey, 1993)
Duane v. Oklahoma Gas & Electric Co.
1992 OK 97 (Supreme Court of Oklahoma, 1992)
Coffman v. Keene Corp.
608 A.2d 416 (New Jersey Superior Court App Division, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
532 P.2d 1377, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cunningham-v-charles-pfizer-co-inc-okla-1975.